Procalcitonin algorithm to guide initial antibiotic therapy in acute exacerbations of COPD admitted to the ICU: a randomized multicenter study

Intensive Care Medicine

Volumn 44, Issue 4, 2018, Pages 428-437

  Daubin, Cédric ^a   Valette, Xavier ^a   Thiollière, Fabrice ^b   Mira, Jean Paul ^c   Hazera, Pascal ^d   Annane, Djillali ^e,f   Labbe, Vincent ^g   Floccard, Bernard ^h   Fournel, François ^a   Terzi, Nicolas ^i,j   Du Cheyron, Damien ^a   Parienti, Jean Jacques ^a,k   Djillali, Annane ^l   Julien, Bohe ^l   Mehdi, Bousta ^l   Jennifer, Brunet ^l   Olivier, Cabon ^l   Pierre, Charbonneau ^l   Cédric, Daubin ^l   Fabrice, Daviaud ^l   Damien, Du Cheyron ^l   Muriel, Fartoukh ^l   Bernard, Floccard ^l   Pascal, Hazera ^l   Vincent, Labbe ^l   Jean Paul, Mira ^l   Andréa, Polito ^l   Michel, Ramakers ^l   Jean Philippe, Rigaud ^l   Bertrand, Sauneuf ^l   Amélie, Seguin ^l   Fabrice, Thiollière ^l   Xavier, Valette ^l   more..

^a CAEN UNIVERSITY HOSPITAL   (France)

^b CENTRE HOSPITALIER LYON SUD   (France)

^c Institut Cochin   (France)

^d General Hospital   (France)

^e RAYMOND POINCARÉ HOSPITAL   (France)

^f University of Versailles Saint Quenti en Yvelines   (France)

^g ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^h EDOUARD HERRIOT HOSPITAL   (France)

ⁱ GRENOBLE UNIVERSITY HOSPITAL   (France)

^j UNIV GRENOBLE ALPES   (France)

^k UNIVERSITÉ DE ROUEN   (France)

^l NONE

more..

Author keywords

Antibiotic stewardship; Chronic obstructive pulmonary disease; Community acquired pneumonia; Procalcitonin; Respiratory tract infection; Viral infection

Indexed keywords

AMINOPENICILLIN; CEPHALOSPORIN DERIVATIVE; MACROLIDE; PENICILLIN DERIVATIVE; PROCALCITONIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT; BIOLOGICAL MARKER;

ADULT; AGED; ALGORITHM; ANTIBIOTIC THERAPY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE EXACERBATION; FEMALE; FRANCE; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; ACUTE DISEASE; BACTERIAL INFECTION; BLOOD; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; INTENSIVE CARE UNIT; MIDDLE AGED; PROSPECTIVE STUDY;

ACUTE DISEASE; AGED; ALGORITHMS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BIOMARKERS; CLINICAL PROTOCOLS; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PROCALCITONIN; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 85045430786     PISSN: 03424642     EISSN: 14321238     Source Type: Journal    
DOI: 10.1007/s00134-018-5141-9     Document Type: Article

References (33)

1. Woodhead M, Blasi F, Ewig S, Garau J, Huchon G, Ieven M, Ortqvist A, Schaberg T, Torres A, van der Heijden G, Read R, Verheij TJ, Joint Taskforce of the European Respiratory Society and European Society for Clinical Microbiology and Infectious Diseases (2011) Guidelines for the management of adult lower respiratory tract infections–full version. Clin Microbiol Infect 17(Suppl 6):E1–E59
2. Soler N, Torres A, Ewig S, Gonzalez J, Celis R, El-Ebiary M, Hernandez C, Rodriguez-Roisin R (1998) Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am J Respir Crit Care Med 157:1498–1505
3. Cameron RJ, de Wit D, Welsh TN, Ferguson J, Grissell TV, Rye PJ (2006) Virus infection in exacerbations of chronic obstructive pulmonary disease requiring ventilation. Intensive Care Med 32:1022–1029
4. Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M, Müller B (2004) Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 363:600–607
5. Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, Widmer I, Neidert S, Fricker T, Blum C, Schild U, Regez K, Schoenenberger R, Henzen C, Bregenzer T, Hoess C, Krause M, Bucher HC, Zimmerli W, Mueller B (2009) ProHOSP Study Group. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 302:1059–1066
6. Christ-Crain M, Stolz D, Bingisser R, Müller C, Miedinger D, Huber PR, Zimmerli W, Harbarth S, Tamm M, Müller B (2006) Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia. Am J Respir Crit Care Med 174:84–93
7. Stolz D, Christ-Crain M, Bingisser R, Leuppi J, Miedinger D, Müller C, Huber P, Müller B, Tamm M (2007) Antibiotic treatment of exacerbations of COPD, a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 131:9–19
8. Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J (2008) Use of procalcitonin to shorten antibiotic treatment duration in septic patients. Am J Respir Crit Care Med 177:498–505
9. Bouadma L, Luyt CE, Tubach F, Cracco C, Alvarez A, Schwebel C, Schortgen F, Lasocki S, Veber B, Dehoux M, Bernard M, Pasquet B, Régnier B, Brun-Buisson C, Chastre J, Wolff M, PRORATA trial group (2010) Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 375:463–474
10. de Jong E, van Oers JA, Beishuizen A, Vos P, Vermeijden WJ, Haas LE, Loef BG, Dormans T, van Melsen GC, Kluiters YC, Kemperman H, van den Elsen MJ, Schouten JA, Streefkerk JO, Krabbe HG, Kieft H, Kluge GH, van Dam VC, van Pelt J, Bormans L, Otten MB, Reidinga AC, Endeman H, Twisk JW, van de Garde EM, de Smet AM, Kesecioglu J, Girbes AR, Nijsten MW, de Lange DW (2016) Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis 16:819–827
11. Stolz D, Smyrnios N, Eggimann P, Pargger H, Thakkar N, Siegemund M, Marsch S, Azzola A, Rakic J, Mueller B, Tamm M (2009) Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study. Eur Respir 34:1364–1375
12. Daubin C, Parienti JJ, Fradin S, Vabret A, Ramakers M, Terzi N, Freymuth F, Charbonneau P, du Cheyron D (2009) Procalcitonin levels and bacterial aetiology among COPD patients admitted to the ICU with severe pneumonia: a prospective cohort study. BMC Infect Dis 21:157
13. Daubin C, Parienti JJ, Vabret A, Ramakers M, Fradin S, Terzi N, Freymuth F, Charbonneau P, du Cheyron D (2008) Procalcitonin levels in acute exacerbation of COPD admitted in ICU: a prospective cohort study. BMC Infect Dis 8:145
14. Conférence de consensus en thérapeutique anti-infectieuse (2006) Prise en charge des infections des voies respiratoires basses de l’adulte immunocompétent. Med Malad infect 36:235–244
15. Rodriguez-Roisin R (2000) Toward a consensus definition for COPD exacerbations. Chest 117:398S–401S
16. Lieberman D, Lieberman D, Gelfer Y, Varshavsky R, Dvoskin B, Leinonen M, Friedman MG (2002) Pneumonic vs nonpneumonic acute exacerbations of COPD. Chest 122:1264–1270
17. Le Gall JR, Lemeshow S, Saulnier F (1993) A new Simplified Acute Physiology Score (SAPS II) based on a European/ North American multicenter study. J Am Med Assoc 270:2957–2963
18. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, Reinhart CK, Suter PM, Thijs LG (1996) The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med 22:707–710
19. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN (1997) A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 336:243–250
20. Kristoffersen KB, Søgaard OS, Wejse C, Black FT, Greve T, Tarp B, Storgaard M, Sodemann M (2009) Antibiotic treatment interruption of suspected lower respiratory tract infections based on a single procalcitonin measurement at hospital admission—a randomized trial. Clin Microbiol Infect 15:481–487
21. Long W, Deng X, Zhang Y, Lu G, Xie J, Tang J (2011) Procalcitonin guidance for reduction of antibiotic use in low-risk outpatients with community-acquired pneumonia. Respirology 16:819–824
22. Corti C, Fally M, Fabricius-Bjerre A, Mortensen K, Jensen BN, Andreassen HF, Porsbjerg C, Knudsen JD, Jensen JU (2016) Point-of-care procalcitonin test to reduce antibiotic exposure in patients hospitalized with acute exacerbation of COPD. Int J Chron Obstruct Pulmon Dis 22:1381–1389
23. Bloos F, Trips E, Nierhaus A, Briegel J, Heyland DK, Jaschinski U, Moerer O, Weyland A, Marx G, Gründling M, Kluge S, Kaufmann I, Ott K, Quintel M, Jelschen F, Meybohm P, Rademacher S, Meier-Hellmann A, Utzolino S, Kaisers UX, Putensen C, Elke G, Ragaller M, Gerlach H, Ludewig K, Kiehntopf M, Bogatsch H, Engel C, Brunkhorst FM, Loeffler M, Reinhart K, for SepNet CriticalCare Trials Group (2016) Effect of sodium selenite administration and procalcitonin-guided therapy on mortality in patients with severe sepsis or septic shock: a randomized clinical trial. JAMA Intern Med 176:1266–1276
24. Layios N, Lambermont B, Canivet JL, Morimont P, Preiser JC, Garweg C, Ledoux D, Frippiat F, Piret S, Giot JB, Wiesen P, Meuris C, Massion P, Leonard P, Nys M, Lancellotti P, Chapelle JP, Damas P (2012) Procalcitonin usefulness for the initiation of antibiotic treatment in intensive care unit patients. Crit Care Med 40:2304–2309
25. Shehabi Y, Sterba M, Garrett PM, Rachakonda KS, Stephens D, Harrigan P, Walker A, Bailey MJ, Johnson B, Millis D, Ding G, Peake S, Wong H, Thomas J, Smith K, Forbes L, Hardie M, Micallef S, Fraser JF, ProGUARD Study Investigators; ANZICS Clinical Trials Group (2014) Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis. A randomized controlled trial. Am J Respir Crit Care Med 190:1102–1110
26. Hochreiter M, Köhler T, Schweiger AM, Keck FS, Bein B, von Spiegel T, Schroeder S (2009) Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Crit Care 13:R83
27. Schroeder S, Hochreiter M, Koehler T, Schweiger AM, Bein B, Keck FS, von Spiegel T (2009) Procalcitonin (PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study. Langenbecks Arch Surg 394:221–226
28. Heyland DK, Johnson AP, Reynolds SC, Muscedere J (2011) Procalcitonin for reduced antibiotic exposure in the critical care setting: a systematic review and an economic evaluation. Crit Care Med 39:1792–1799
29. Prkno A, Wacker C, Brunkhorst FM, Schlattmann P (2013) Procalcitonin-guided therapy in intensive care unit patients with severe sepsis and septic shock—a systematic review and meta-analysis. Crit Care 17:R291
30. Schuetz P, Wirz Y, Sager R, Christ-Crain M, Stolz D, Tamm M, Bouadma L, Luyt CE, Wolff M, Chastre J, Tubach F, Kristoffersen KB, Burkhardt O, Welte T, Schroeder S, Nobre V, Wei L, Bucher HC, Annane D, Reinhart K, Falsey AR, Branche A, Damas P, Nijsten M, de Lange DW, Deliberato RO, Oliveira CF, Maravić-Stojković V, Verduri A, Beghé B, Cao B, Shehabi Y, Jensen JS, Corti C, van Oers JAH, Beishuizen A, Girbes ARJ, de Jong E, Briel M, Mueller B (2018) Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. Lancet Infect Dis 18:95–107
31. Huang HB, Peng JM, Weng L, Wang CY, Jiang W, Du B (2017) Procalcitonin-guided antibiotic therapy in intensive care unit patients: a systematic review and meta-analysis. Ann Intensive Care 7:114
32. Jensen JU, Hein L, Lundgren B, Bestle MH, Mohr TT, Andersen MH, Thornberg KJ, Løken J, Steensen M, Fox Z, Tousi H, Søe-Jensen P, Lauritsen AØ, Strange D, Petersen PL, Reiter N, Hestad S, Thormar K, Fjeldborg P, Larsen KM, Drenck NE, Ostergaard C, Kjær J, Grarup J, Lundgren JD, Procalcitonin And Survival Study (PASS) Group (2011) Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. Crit Care Med 39(9):2048–2058
33. Vollenweider DJ, Jarrett H, Steurer-Stey CA, Garcia-Aymerich J, Puhan MA (2012) Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 12:CD010257